With special regard to immuno-PET imaging in NSCLC patients, several clinical trials are currently underway evaluating several novel ligands such as 89Zr-avelumab (NCT03514719, PINNACLE), 89Zr-durvalumab (2015-005765-23), 99mTc-anti-PD-L1 (sdAb) single-photon emission computed tomography (SPECT) (NCT02978196), or combined imaging with 89Zr-durvalumab PET and 111In-CD8 T cell SPECT (NCT03853187, DONAN). The gene discussed is CD8A; the disease is non-small cell lung carcinoma.